spacer
home > ebr > spring 2017 > becoming better informed
PUBLICATIONS
European Biopharmaceutical Review

Becoming Better Informed

Increasing success rates and speed to failure requires more information. We need to know which proteins to target, which molecules to use and to which patients drugs should be administered. The devil, as always, is in the details. Cell-based screening, computational modelling and ribosomal profiling, among other recent improvements, are informative but do not seem to be the solution. Clearly, another approach is needed. Mine is premised on three assumptions:

  1. Proteomics represents the most abundant and useful pool of biological information
  2. Post-translational modification (PTM) is the defining feature of human proteins
  3. Mass spectrometry (MS) is a structurally flawed tool for accessing these data

Proteomics is King

Blueprints and recipes contain assembly instructions; genomes do not. Our approximately 20,000 human genes get spliced into about 100,000 unique transcripts variable across development and cell type (1). TP53, one of the best-studied proteins in humans, has at least 15 structurally and functionally distinct isoforms (2). In point of fact, the previous statement betrays a biological error shared by MS namely that TP53 is a gene, not a protein. Ignoring splice variation makes conversation simpler, but masks the molecular complexity we require to exist and survive.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian Loch is co-founder and Director of R&D at AVMBioMed. He is also adjunct faculty in the Department of Chemistry at Villanova University, US, where he teaches proteomics in the graduate school. Christian has 10 years of industry experience and holds an MPH in Epidemiology from the University of Washington, US, and a PhD in Biochemistry from the University of Virginia, US.
spacer
Christian Loch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

H&T Presspart and Hovione Technology Enter Dry Powder Inhalation Partnership


More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

Outsourcing in Clinical Trials Medical Devices 2017

27-28 June 2017, Santa Clara, CA

OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement